S
SYRE
Spyre Therapeutics
47.58
-1.32-2.70%After Hours: 48.06 +0.48 +1.01%19:09 04/02 EDT
OPEN/PREV CLOSE48.97/48.98
TODAY RANGE48.83-51.26
VOL799.42K
MARKET CAP4.02B
52 WEEK RANGE10.91-51.26
AVG VOL (3M)737.24K
% TURNOVER1.02%
TURNOVER--
P/E (TTM)-21.1317
% RANGE4.97%
EPS(TTM)-2.4229
P/E(FORWARD)-17.3854
P/B5.60
BVPS9.15
DIVIDEND--
P/S1,244.31
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.59B
SHARES OUTSTANDING78.54M
NEXT EARNINGS05/06-05/11
FREE FLOAT70.10M
LOT SIZE1
EX-DATE09/08/2023
News
Press Releases
Financial Reports
Profile
Simply Wall St·2d ago
Assessing Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Progress And Strong Share Price Momentum
Dow Jones·03/31 10:40
Spyre Therapeutics Price Target Maintained With a $70.00/Share by BTIG
Benzinga·03/31 10:31
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $70 Price Target
Simply Wall St·03/30 10:11
Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy?
TipRanks·03/23 12:23
Damora names Peter Harwin chairman, appoints Spyre Therapeutics CEO to board
TipRanks·03/22 17:35
Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)
TipRanks·03/21 14:55
Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst
NASDAQ·03/19 02:54
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools
Same Industry
Name/Symbol
Change%
Price